Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Restraint, Physical × Dermatologic × Clear all
NCT04990726 2026-02-27

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

M.D. Anderson Cancer Center

Active not recruiting
126 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡